2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Apolipoprotein

Apolipoprotein

Plasma lipoprotein metabolism is regulated and controlled by the specific apolipoprotein (apo-) constituents of the various lipoprotein classes. The major apolipoproteins include apoE, apoB, apoA-I, apoA-II, apoA-IV, apoC-I, apoC-II, and apoC-III. Specific apolipoproteins function in the regulation of lipoprotein metabolism through their involvement in the transport and redistribution of lipids among various cells and tissues, through their role as cofactors for enzymes of lipid metabolism, or through their maintenance of the structure of the lipoprotein particles.

Apolipoprotein Isoform Specific Products:

Apolipoprotein Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-RS00846
    APOC3 Human Pre-designed siRNA Set A
    		Inhibitor

    APOC3 Human Pre-designed siRNA Set A contains three designed siRNAs for APOC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    APOC3 Human Pre-designed siRNA Set A
    APOC3 Human Pre-designed siRNA Set A
  • HY-P6306A
    CS-6253 TFA
    		Agonist 98.53%
    CS-6253 TFA is the TFA salt form of CS-6253 (HY-P6306). CS-6253 TFA is an agonist for ATP-binding cassette 1 (ABCA 1). CS-6253 TFA improves the amyloid-β42/40 ratio, and affects lipoprotein metabolism in plasma. CS-6253 TFA generates cholesterol-rich high-density lipoprotein (HDL) particles, and induces the release of microparticles.
    CS-6253 TFA
  • HY-147425
    Zerlasiran
    		Inhibitor
    Zerlasiran is an apolipoprotein A (ApoA) synthesis reducer.
    Zerlasiran
  • HY-153491
    Olezarsen
    		Inhibitor
    Olezarsen is an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels in patients at high risk for or with established cardiovascular disease.
    Olezarsen
  • HY-169932
    APOL1-IN-2
    		Inhibitor
    APOL1-IN-2 (Compound 467) is the inhibitor for Apolipoprotein 1 (APOL1). APOL1-IN-2 reduces the APOL1 G2/G1 induced cell death in HEK293 with EC50 of 4.74 nM and 14.3 nM. APOL1-IN-2 reduces the APOL1 G2/G1/G0 induced death of trypanosomes with EC50 of 2.24, 6.03 and 3.72 nM, respectively.
    APOL1-IN-2
  • HY-169080
    ABCA1 inducer 1
    		Inducer
    ABCA1 inducer 1 is a nonlipogenic ABCA1 inducer. ABCA1 inducer 1 increases ABCA1 expression, enhances apolipoprotein (APOE) lipidation and reverses multiple Alzheimer’s disease (AD) phenotypes, without increasing triglycerides in E3/4FAD mice that express human APOE 3/4.
    ABCA1 inducer 1
  • HY-164740A
    Plozasiran sodium
    		Inhibitor
    Plozasiran sodium is an siRNA targeting APOC3 for the study of mixed hyperlipidemia.
    Plozasiran sodium
  • HY-165061
    5(Z),11(Z),14(Z)-Eicosatrienoic acid
    		Inhibitor
    5(Z),11(Z),14(Z)-Eicosatrienoic acid (Sciadonic acid), a polyunsaturated fatty acid sourced from maritime pine seed oil, gymnospermae leaves and seeds, and freshwater gastropods, has been shown to reduce high-density lipoprotein and ApoA1 levels in transgenic mice expressing human ApoA1 when included in their diet. In vitro studies indicate that it diminishes cholesterol efflux, and when applied topically in its methyl ester form, it alleviates inflammatory processes, likely by displacing arachidonic acid from phospholipid pools and lowering concentrations of downstream inflammatory mediators such as prostaglandin E2 and leukotrienes.
    5(Z),11(Z),14(Z)-Eicosatrienoic acid
  • HY-P6365B
    APP-018
    APP-018 (D-4F) is 18 D-amino acids peptide that mimics apolipoprotein A-I (apoA-I). APP-018 improves the anti-inflammatory activity of high-density lipoprotein (HDL). APP-018 can be used in researches of cardiovascular diseases.
    APP-018
  • HY-164740
    Plozasiran
    		Inhibitor
    Plozasiran is an siRNA targeting APOC3 for the study of mixed hyperlipidemia.
    Plozasiran
  • HY-148647
    Mipomersen
    		Inhibitor
    Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen can be used for the research of homozygous familial hypercholesterolemia (HoFH).
    Mipomersen
  • HY-173323
    Lp(a)-IN-7
    		Inhibitor
    Lp(a)-IN-2 (example 1) is a lipoprotein (a) (Lp(a)) formation inhibitor with an IC50 of 2.51 nM in conditioned media containing apolipoprotein B (apoB) and apolipoprotein(a). LPA2 antagonist 4 can be used for the study of cardiovascular disease.
    Lp(a)-IN-7
  • HY-P10188
    apoB (4372-4392)
    		Inhibitor
    apoB (4372-4392) is a potent lipoprotein(a) assembly inhibitor, with an IC50 of 40 μM. apoB (4372-4392) can noncovalently bind to apolipoprotein(a) with high affinity.
    apoB (4372-4392)
  • HY-121417
    Laserpitin
    Laserpitin, a coumarin, increases serum HDL levels, especially apoE-HDL, and decreases the hepatic triglyceride content in stroke-prone spontaneously hypertensive rats (SHRSP).
    Laserpitin
Apolipoprotein Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.